Conference
Clinical evidence from ONTARGET: proven cardio- and vascular protection
Abstract
ONTARGET compared the angiotensin II receptor blocker telmisartan with the angiotensin-converting enzyme (ACE) inhibitor ramipril, and the two agents in combination with ramipril alone, in a broad cross section of patients with vascular disease or high-risk diabetes without heart failure. Telmisartan was as effective as the gold standard ramipril in the prevention of cardiovascular death, myocardial infarction, stroke, or hospitalization for …
Authors
Teo KK
Volume
11
Pagination
pp. f9-f15
Publisher
Oxford University Press (OUP)
Publication Date
December 1, 2009
DOI
10.1093/eurheartj/sup032
Conference proceedings
European Heart Journal Supplements
Issue
suppl_F
ISSN
1520-765X